Introduction
Glaucoma and ocular hypertension are progressive, vision-threatening conditions associated with increased intraocular pressure (IOP). Quigley and Broman have reported that, by 2020, more than 28 million people in Asia and nearly 60 million people worldwide will be diagnosed with open-angle glaucoma. 1 In Japan, glaucoma is the leading cause of visual impairment. 2 Reducing IOP is currently the only established treatment for slowing or preventing progression of open-angle glaucoma and ocular hypertension, 3 which, if untreated, can lead to visual field defects and blindness. 4 Multiple classes of IOP-lowering agents have been developed for therapeutic use, including carbonic anhydrase inhibitors and beta-adrenergic receptor antagonists (β-blockers). 3 Systemic administration of carbonic anhydrase inhibitors and β-blockers, among other agents, can produce adverse effects, including malaise, fatigue, and sleep disturbances; 5, 6 as a result, ophthalmic instillation has been pursued as a route of administration for treatment of glaucoma and ocular hypertension.
Many patients require multiple ocular hypotensive agents to achieve sufficient IOP reduction. 7 Topical treatment with the nonselective β-blocker timolol 0.5% (TIM) and an adjunctive agent to lower IOP has become increasingly common. 3, 8 Concomitant therapy with topical brinzolamide 1% (BRINZ), a carbonic anhydrase inhibitor, and TIM has been demonstrated to significantly decrease IOP in patients with glaucoma or ocular hypertension. [9] [10] [11] Both BRINZ and TIM, individually and in combination, are generally well tolerated. [10] [11] [12] [13] [14] Concomitant administration of multiple topical agents has been associated with drug washout, increased complexity of administration, and decreased treatment compliance; these factors can decrease delivery of effective doses of ocular hypotensives. [15] [16] [17] Fixed-combination pharmacotherapies of IOP-lowering agents eliminate risk of washout and simplify drug administration. 16, 17 The safety and efficacy of fixed-combination brinzolamide 1%/timolol 0.5% (BRINZ/ TIM-FC) have been established in adult patients with glaucoma or ocular hypertension; because BRINZ/TIM-FC has been marketed in the European Union, earlier studies included mostly white or black patients and relatively few Asian patients. [18] [19] [20] [21] [22] In a double-masked, parallel-group study, BRINZ/TIM-FC achieved significantly superior IOP reduction compared with BRINZ or TIM monotherapy. 22 Furthermore, patients transitioned to BRINZ/TIM-FC (usually because of insufficient IOP reduction with or intolerance to their previous treatment) achieved significant IOP reductions from baseline after 4-6 weeks of therapy, and nearly 90% of patients judged the tolerability of BRINZ/TIM-FC positively. 19 The objective of this randomized, double-masked, multicenter, parallel-group, controlled study was to evaluate the safety and efficacy of BRINZ/TIM-FC compared with concomitant therapy of unfixed BRINZ and TIM (BRINZ + TIM) in Japanese patients with open-angle glaucoma or ocular hypertension. The main hypothesis tested was that the IOP-lowering efficacy of BRINZ/TIM-FC is similar to that of BRINZ + TIM.
Materials and methods study design
This was a Phase III, randomized, double-masked, multicenter, parallel-group, positive-controlled study ( Figure 1 ) conducted at 34 sites in Japan. At the screening visit (week -4), patients gave their written informed consent to participate in the study and were evaluated for inclusion and exclusion criteria and use of prohibited or restricted concomitant drugs. Use of other IOP-lowering agents was suspended for the duration of the study. Patients were instructed to administer TIM twice daily at 9 am (±30 minutes) and 9 pm (±30 minutes) until the baseline visit (observation phase). At the baseline visit (week 0), conducted 28±7 days after screening, eligibility was confirmed based on inclusion and exclusion criteria and compliance with TIM therapy during the observation phase. Patients were randomized to BRINZ/TIM-FC or BRINZ + TIM treatment groups and instructed to instill the appropriate active agent(s) or placebo (ie, BRINZ/TIM-FC and matched placebo or BRINZ and TIM) twice daily, at 9 am 
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Fixed versus unfixed combination of brinzolamide and timolol (±30 minutes) and 9 pm (±30 minutes), for 8 weeks (treatment phase). Efficacy and safety endpoints were assessed at 9 am (before instillation of ophthalmic solutions) and 11 am (2 hours post instillation) at baseline, week 4, and week 8. A total of 24 sites also performed efficacy and safety assessments at 4 pm (7 hours post instillation).
The institutional review board of each participating institution reviewed and approved the study protocol, and the study was conducted according to the Declaration of Helsinki.
Patients
Study participants were Japanese patients aged $20 years with a diagnosis of open-angle glaucoma (primary openangle glaucoma, exfoliation glaucoma, pigmentary glaucoma) or ocular hypertension for whom TIM monotherapy provided insufficient IOP reduction. Patients were eligible for participation if IOP in at least one eye was in the range of 18-36 mmHg at both 9 am and 11 am at the baseline visit (week 0), with neither eye .36 mmHg. Key exclusion criteria included a history of chronic or recurrent severe ocular inflammatory disease, ocular trauma or intraocular surgery within 6 months or laser eye surgery within 3 months of screening, ocular infection or endophthalmitis, retinal disease, hypersensitivity to study drugs, or use of confounding ophthalmic or systemic drugs (unless on a stable dosage regimen with no new administration from screening to the end of the treatment phase). Additionally, patients with maximum corrected visual acuity #0.2 (decimal acuity) or an anterior chamber angle grade ,2 in either eye were excluded.
Treatment
During the observation phase (week −4 to week 0), all patients instilled one drop of TIM aqueous ophthalmic solution in each eye twice daily. Throughout the treatment phase (week 0 to week 8), patients instilled either a placebo (an aqueous ophthalmic solution containing no active ingredient) followed by BRINZ/TIM-FC ophthalmic suspension (Azarga ® ; Alcon Laboratories, Inc, Fort Worth, TX, USA) or TIM followed by BRINZ ophthalmic suspension (Alcon Laboratories, Inc), with concomitant instillations $5 minutes apart twice daily. At the screening visit, patients were provided with a journal and requested to record the conditions of investigational drug instillation and any changes in concomitant drugs.
Efficacy assessments
The primary efficacy endpoint was mean IOP change from baseline at 11 am (2 hours post instillation) at the week 8 visit.
Similarity of the IOP-lowering efficacy of BRINZ/TIM-FC versus BRINZ + TIM was evaluated (margin of noninferiority, +1.1 mmHg). Secondary efficacy endpoints included mean IOP over time. IOP was measured by Goldmann applanation tonometry at screening and at 9 am, 11 am, and 4 pm at baseline, week 4, and week 8.
safety assessments
Adverse events were assessed at the baseline, week 4, and week 8 visits. Solicited and unsolicited adverse events were recorded at each visit and coded using the Medical Dictionary for Regulatory Activities Japanese translation, version 14.1. The following safety parameters were assessed at screening, baseline, week 4, and week 8: best corrected visual acuity (decimal acuity scale), slit lamp examination (cornea, eyelid/conjunctiva, iris/anterior chamber, lens), blood pressure, and pulse rate. Funduscopy (vitreous, retina/ macula/choroid, optic nerve, optic nerve cup-to-disc ratio), gonioscopy (anterior chamber angle grade), static perimetry (visual field stage, defined using Greve's modification of the Aulhorn classification 23 ), and laboratory tests (hematology, serum chemistry, and qualitative urinalysis) were performed at screening and week 8.
statistical analyses
Mean changes in IOP from baseline for each group and the difference between groups were estimated with 95% confidence intervals (CIs) by a repeated-measures analysis of covariance model with baseline IOP values used as the covariate. Significance of the primary endpoint, ie, IOP reduction from baseline at the 11 am week 8 assessment, was determined by paired t-tests. Descriptive statistics were obtained for mean ± standard deviation IOP and IOP change from baseline throughout the study. Noninferiority of BRINZ/TIM-FC versus BRINZ + TIM was considered to be proven if the upper limit of the one-sided 97.5% CI of the difference between treatment groups in mean IOP change from baseline at 11 am at week 8 was ,1.1 mmHg. Post hoc analyses of treatment group differences in incidence of adverse events were performed using Fisher's Exact tests.
Group sizes and statistical power were determined before initiation of the study. Assuming a standard deviation of 3.0 mmHg for the IOP change from baseline, sample sizes of $135 patients per group were determined to be sufficient to detect a difference in IOP $1.1 mmHg within the coverage probability of the 97.5% upper CI with 85% power.
Efficacy was analyzed in the per-protocol population (defined as all patients who received study medication in the treatment phase, had post-administration tests and observation data, and satisfied the protocol criteria) and the intent-to-treat population (defined as all patients who received study medication in the treatment phase and who had post-administration tests and observation data). Safety variables were analyzed in the safety population (defined as all patients who received study medication).
Results

Patients
A total of 366 patients were enrolled in the observation phase. Of these, 319 continued into the treatment phase (BRINZ/TIM-FC, n=158; BRINZ + TIM, n=161; mean age 64±12 years) and were included in the intent-to-treat data set (ie, all patients administered an investigational drug for whom post-administration tests and observation data existed). A total of 309 completed the study and were included in the per-protocol population. Forty-seven patients discontinued the study during the observation phase; the most frequent reasons for discontinuation from the observation phase were selection criteria (n=25), meeting exclusion criteria (n=10), and adverse events (n=8). Ten patients discontinued the study during the treatment phase (Figure 2 ). Eleven cases of noncompliance occurred, five of which resulted in discontinuation.
Baseline demographic and diagnosis information for the per-protocol population are presented in Table 1 . The treatment groups were balanced with regard to age, sex, and diagnosis. The majority of patients (56%) were diagnosed with primary open-angle glaucoma, followed by ocular hypertension (41%). No patients were diagnosed with normal-tension glaucoma.
Efficacy
Efficacy for the per-protocol and intent-to-treat populations was similar throughout the study; therefore, the efficacy data presented here are only from the per-protocol data set. Table 4 ). The most frequently reported treatmentrelated adverse events were blurred vision and eye irritation ( Table 4 Additional visual and ophthalmic safety parameters, including best corrected visual acuity, visual field, optic nerve cup-to-disc ratio, angle grade, and intraocular and external features assessed by slit-lamp and funduscopy were largely unchanged from baseline to week 8. Deterioration in visual field score from baseline was observed in 3% (n=5/156) of patients who received BRINZ/TIM-FC and 7% (n=11/161) of patients who received BRINZ + TIM.
There were no substantial variations in hematology, serum chemistry, or urinalysis parameters in either treatment group over time. Many changes in laboratory measurements were within the range of physiologic variation. Further, no substantial variations in blood pressure or pulse rate were observed.
Discussion
The primary treatment approach for glaucoma and ocular hypertension is to reduce IOP and prevent disease progression. 3, 7 Clinical studies have demonstrated that multiple hypotensive agents are often required to achieve sufficient IOP reduction. 7, 24 Increasing use of multiple antiglaucoma medications over time was previously observed in Japanese patients. 25 Fixed-combination pharmacotherapies of multiple ocular hypotensive agents, including BRINZ/ TIM-FC, were shown to reduce IOP in patients with glaucoma and ocular hypertension, with greater efficacy than their component monotherapies. 22, [26] [27] [28] Furthermore, compared with unfixed combination therapies (ie, multiple medication bottles), fixed-combination therapies can decrease cumulative patient exposure to preservatives, reduce risk of drug washout, and simplify drug administration. [15] [16] [17] 29 The goal of the current study was to evaluate the safety and efficacy of BRINZ/TIM-FC compared with unfixed concomitant BRINZ + TIM in Japanese patients with −0.4 to 0.8 −0.5 to 0.7 −0.6 to 0.5 −0.5 to 0.6 −0.8 to 0.3 −0.7 to 0.4
Notes: *All data are mmHg; † estimates based on LS mean using repeated-measures analysis of covariance adjusted with baseline IOP; ‡ primary endpoint. Abbreviations: BrinZ + TIM, unfixed concomitant brinzolamide 1% and timolol 0.5%; BRINZ/TIM-FC, brinzolamide 1%/timolol 0.5% fixed combination; CI, confidence interval; IOP, intraocular pressure; LS, least squares. The safety and efficacy of BRINZ/TIM-FC and BRINZ + TIM in this study were consistent with those reported in previous studies of these agents as combination therapy and monotherapy in other patient populations. 10, 11, 18, 19, 21, 22, 30, 31 Similar to the current study, which demonstrated comparable efficacy of BRINZ/TIM-FC and unfixed concomitant BRINZ + TIM, other clinical assessments of fixed-combination therapies have demonstrated that fixed-combination pharmacotherapies containing TIM and dorzolamide, a carbonic anhydrase inhibitor, or latanoprost, a prostaglandin analog, have efficacy similar to that of concomitant treatment with their active components. [32] [33] [34] [35] Fixed-combination dorzolamide 1%/TIM is approved for use in Japan; there are currently no comparative data for BRINZ/TIM-FC versus the fixed combination of dorzolamide 1%/TIM. However, in a previous multinational noninferiority study conducted in Europe, BRINZ/TIM-FC produced IOP reductions similar to those achieved with fixed-combination dorzolamide 2%/TIM. 20 Further, studies conducted in the US and South America indicate that among patients with a treatment preference, BRINZ/TIM-FC was favored by patients over fixed-combination dorzolamide 2%/ TIM. 21, 31 This result may be attributable to the increased severity and duration of ocular discomfort with dorzolamide 2%/ TIM compared with BRINZ/TIM-FC. 18, 21, 31, 36 Patients in the current study reported a low incidence of dysgeusia, a result that may be related to adequate informed consent (including explanation of adverse events) before study participation.
Based on the similar IOP-lowering efficacy of BRINZ/ TIM-FC and BRINZ + TIM, BRINZ/TIM-FC is expected to provide a benefit to patients with glaucoma as a substitute for unfixed concomitant BRINZ + TIM in terms of both treatment convenience and compliance. Additional studies are needed to confirm this hypothesis. A potential limitation of the current study is that the study population did not include any patients with normal-tension or closed-angle glaucoma; both of these conditions are common in people of Japanese descent. 1, 37 Additionally, future studies of patients with pigmentary or exfoliation open-angle glaucoma are needed; because of the small numbers of patients with these glaucoma etiologies in the current study, conclusions regarding the safety and efficacy of BRINZ/TIM-FC in these patients should be made with caution. 
Conclusion
Treatment with twice-daily BRINZ/TIM-FC significantly reduced IOP throughout this 8-week study in Japanese patients with open-angle glaucoma or ocular hypertension. IOP-lowering efficacy was similar with BRINZ/TIM-FC and BRINZ + TIM. Further, the safety profiles of BRINZ/ TIM-FC and BRINZ + TIM were similar, and both therapies were well tolerated. 
